Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
| Study title | Condition | Phase | Location | |
|---|---|---|---|---|
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria |
Uncomplicated Plasmodium Falciparum Malaria | Phase2 | Burkina Faso Côte D'Ivoire Gabon Ghana Kenya Uganda View All |
NCT05750628 |
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC |
Prostatic Neoplasm | Phase2 | Brazil Canada China Czechia France Germany Italy Korea, Republic of Netherlands Poland Singapore Spain United States View All |
NCT05849298 |
A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN) |
Lupus Erythematosus, Systemic, Lupus Nephritis | Phase2 | France Germany Italy Japan Netherlands Singapore Spain United States View All |
NCT06581198 |
Secukinumab Open Label Roll-over Extension Protocol |
Autoimmunity, Inflammation | Phase4 | Brazil Bulgaria China Colombia Czechia Guatemala Italy Poland Portugal Russian Federation South Africa Spain Switzerland United States View All |
NCT04638647 |
Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT |
Prostate Cancer | Phase1, Phase2 | Australia Canada France |
NCT05983198 |
Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis |
Multiple Sclerosis | Phase4 | Taiwan | NCT04480853 |
Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission |
Giant Cell Arteritis | Phase3 | Germany | NCT05380453 |
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up |
Chronic Spontaneous Urticaria | Phase3 | Argentina Canada China Germany Hong Kong Italy Japan Malaysia Netherlands Poland Singapore South Africa Spain Thailand Turkey United Kingdom United States View All |
NCT05677451 |
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis |
Lupus Nephritis | Phase3 | Argentina Brazil Canada Chile China Colombia Czechia Estonia France Germany Guatemala Hong Kong Hungary India Italy Korea, Republic of Lithuania Malaysia Mexico Romania Singapore Spain Taiwan Thailand United Kingdom United States Vietnam View All |
NCT05126277 |